GW501516 (also known as GW-501,516, GW1516, GSK-516, cardarine, and amongst performance enhancing drug communities as endurobol) is a PPARδ receptor agonist that was invented in a collaboration between Ligand Pharmaceuticals and GlaxoSmithKline in the 1990s. It entered into clinical development as a drug candidate for metabolic and cardiovascular diseases, but was abandoned in 2007 because animal testing showed that the drug caused cancer to develop rapidly in several organs.
GW501516 (also known as GW-501,516, GW1516, GSK-516, cardarine, and amongst performance enhancing drug communities as endurobol) is a PPARδ receptor agonist that was invented in a collaboration between Ligand Pharmaceuticals and GlaxoSmithKline in the 1990s. It entered into clinical development as a drug candidate for metabolic and cardiovascular diseases, but was abandoned in 2007 because animal testing showed that the drug caused cancer to develop rapidly in several organs.
Source: Wikipedia "GW501516" · CC BY-SA 4.0
Share this article: X · Bluesky